Perinatal risk-indicators for long-term respiratory morbidity among preterm or very low birth weight neonates

Teune, Margreet J.; Wassenaer, Aleid G. van; Buuren, Stef van; Mol, Ben Willem J.; Opmeer, Brent C.

doi:10.1016/j.ejogrb.2012.04.015

Cited by 15 publications

(18 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in contrast to our prior findings with iNO-alone, wherein beneficial effects of iNO in the NO CLD study were seen on both classes of inhaled medications (2). Finally, although data supporting the association of parental asthma and preterm respiratory outcomes are variable, we did plan a sensitivity analysis as this characteristic is of interest with respect to childhood wheezing illness (29, 30). …”

Section: Discussionmentioning

confidence: 99%

The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age

Keller

Eichenwald²,

Hibbs

et al. 2017

The Journal of Pediatrics

View full text Add to dashboard Cite

Objective To determine the effects of late surfactant on respiratory outcomes determined at one-year corrected age In the Trial of Late Surfactant (TOLSURF), which randomized extremely low gestational age newborns (ELGAN, ≤28 weeks’ gestational age) ventilated at 7–14 days to late surfactant and inhaled nitric oxide versus inhaled nitric oxide-alone (control). Study design Caregivers were surveyed in a double-blinded manner at 3, 6, 9 and 12 months corrected age to collect information on respiratory resource utilization (infant medication use, home support and hospitalization). Infants were classified for composite outcomes of Pulmonary Morbidity (No PM, determined in infants with no reported respiratory resource utilization) and Persistent PM (determined in infants with any resource utilization in ≥3 surveys). Results Infants (n=450, late surfactant n=217, control n=233) were 25.3±1.2 weeks’ gestation and 713±164g at birth. In the late surfactant group, fewer infants received home respiratory support than in the control group [35.8% versus 52.9%, Relative Benefit (RB) 1.28 (1.07, 1.55)]. There was no benefit of late surfactant for No PM versus PM (RB 1.27; 95% CI 0.89, 1.81) or No Persistent PM versus Persistent PM (RB 1.01; 95% CI 0.87, 1.17). After adjustment for imbalances in baseline characteristics, relative benefit of late surfactant treatment increased: RB 1.40 (95% CI 0.89, 1.80) for No PM and RB 1.24 (95% CI 1.08, 1.42) for No Persistent PM. Conclusion Treatment of ELGAN with late surfactant in combination with inhaled nitric oxide decreased use of home respiratory support and may decrease persistent pulmonary morbidity. Trial registration ClinicalTrials.gov: NCT01022580

show abstract

Section: Discussionmentioning

confidence: 99%

The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age

Keller

Eichenwald²,

Hibbs

et al. 2017

The Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

“…Despite variations in methods, most studies suggest that CLD is associated with an increased risk of asthma later in life . However, whether airway reactivity is a result of lung injury sustained in the neonatal intensive care unit (NICU) or is due to intrinsic susceptibilities related to prematurity is not clear.…”

Section: Introductionmentioning

confidence: 99%

Risk factors for chronic lung disease and asthma differ among children born extremely preterm

Jackson

Allred

Laughon

et al. 2018

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

“…Maternal smoking is one of the risk factors for preterm birth and intra-uterine growth retardation (Andres and Day, 2000; Delpisheh et al, 2006; Huuskonen et al, 2008; Nieuwenhuijsen et al, 2013; Teune et al, 2012)resulting in serious health problems for the child during the neonatal period, which could in turn lead to chronic lifelong disorders such as cardiovascular disability, cerebral palsy, mental retardation, and even death (Barker et al, 1995; Horta et al, 1997; Jules et al, 2012). Intrauterine smoke exposure could also influence the development of bronchopulmonary dysplasia (BPD) (Antonucci et al, 2004; Singh et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Increased susceptibility to hyperoxic lung injury and alveolar simplification in newborn rats by prenatal administration of benzo[a]pyrene

et al. 2014

View full text Add to dashboard Cite

Maternal smoking is one of the risk factors for preterm birth and for the development of bronchopulmonary dysplasia (BPD). In this study, we tested the hypothesis that prenatal exposure of rats to benzo[a]pyrene (BP), a component of cigarette smoke, will result in increased susceptibility of newborns to oxygen-mediated lung injury and alveolar simplification, and that cytochrome P450 (CYP)1A and 1B1 enzymes and oxidative stress mechanistically contribute to this phenomenon. Timed pregnant Fisher 344 rats were administered BP (25 mg/Kg) or the vehicle corn oil (CO) on gestational days 18, 19 and 20, and newborn were either maintained in room air or exposed to hyperoxia (85% O2) for 7 or 14 days. Hyperoxic newborn rats prenatally exposed to the vehicle CO showed lung injury and alveolar simplification, and inflammation, and these effects were potentiated in rats that were prenatally exposed to BP. Prenatal exposure to BP, followed by hyperoxia, also resulted in significant modulation of hepatic and pulmonary cytochrome P450 (CYP)1A and 1B1 enzymes at PND 7-14. These rats displayed significant oxidative stress in lungs at postnatal day (PND) 14, as evidenced by increased levels of the F2-isoprostane 8-iso-PGF2α. Furthermore, these animals showed BP-derived DNA adducts and oxidative DNA adducts in the lung. In conclusion, our results show increased susceptibility of newborns to oxygen-mediated lung injury and alveolar simplification following maternal exposure to BP, and our results suggest that modulation of CYP1A/1B1 enzymes, increases in oxidative stress, and BP-DNA adducts contributed to this phenomenon.

show abstract

Perinatal risk-indicators for long-term respiratory morbidity among preterm or very low birth weight neonates

Cited by 15 publications

References 11 publications

The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age

The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age

Risk factors for chronic lung disease and asthma differ among children born extremely preterm

Increased susceptibility to hyperoxic lung injury and alveolar simplification in newborn rats by prenatal administration of benzo[a]pyrene

Contact Info

Product

Resources

About